<p>Accuray（納斯達克代碼：ARAY - 獲取免費報告）在週日發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票研究人員將評級從 “持有” 下調至 “賣出”。</p>
<p>其他股票研究分析師也對該股票發佈了研究報告。BTIG Research 在 11 月 6 日的研究報告中將 Accuray 的目標價格從 5.00 美元下調至 4.00 美元，並對該股票給予了 “買入” 評級。Weiss Ratings 在 12 月 22 日的報告中重申了對 Accuray 的 “賣出（d-）” 評級。一位股票研究分析師給予該股票 “買入” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 4.00 美元。</p>
<p><strong>查看我們最新的 ARAY 股票分析</strong></p>
<h2>Accuray 股票表現</h2>
<p>ARAY 股票在週五開盤價為 0.83 美元。該股票的 50 日簡單移動平均為 1.14 美元，200 日簡單移動平均為 1.36 美元。Accuray 的 12 個月低點為 0.81 美元，12 個月高點為 2.95 美元。該公司的市值為 9354 萬美元，市盈率為-5.16，貝塔值為 1.06。該公司的流動比率為 1.56，速動比率為 0.76，債務與股本比率為 2.06。</p>
<p>Accuray（納斯達克代碼：ARAY - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。這家醫療設備提供商報告季度每股收益為（0.18 美元），低於分析師共識預期的（0.05 美元）13 美分。該季度的營業收入為 9394 萬美元，而分析師預期為 9134 萬美元。Accuray 的股本回報率為-34.06%，淨利潤率為-4.28%。作為一個整體，股票研究分析師預測 Accuray 在當前年度將發佈 0.01 美元的每股收益。</p>
<h2>Accuray 的機構交易</h2>
<p>大型投資者最近增加或減少了在該公司的持股。俄亥俄州公共僱員退休系統在第三季度新購入了 Accuray 的股份，價值 35,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Accuray 的持股增加了 604.2%。Tower Research Capital LLC TRC 目前擁有 35,177 股該醫療設備提供商的股票，價值 48,000 美元，此前在該期間內又購買了 30,182 股。BNP Paribas Financial Markets 在第三季度將其在 Accuray 的持股增加了 32.4%。BNP Paribas Financial Markets 目前擁有 39,369 股該醫療設備提供商的股票，價值 66,000 美元，此前在上個季度又購買了 9,633 股。Teton Advisors LLC 在第三季度新購入了價值約 67,000 美元的 Accuray 股份。最後，R Squared Ltd 在第三季度將其在 Accuray 的持股增加了 94.0%。R Squared Ltd 目前擁有 40,550 股該醫療設備提供商的股票，價值 68,000 美元，此前在該期間內又購買了 19,648 股。當前 64.08% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Accuray</h2>
<p>（獲取免費報告）</p>
<p>Accuray Incorporated（納斯達克代碼：ARAY）是一家全球醫療設備公司，開發、製造和銷售創新的放射治療解決方案用於癌症治療。該公司的旗艦產品包括 CyberKnife®系統，這是一種提供亞毫米精度的機器人放射外科平台，以及 TomoTherapy®系統，它將螺旋計算機斷層掃描（CT）成像與強度調製放射治療（IMRT）相結合。最近，Accuray 推出了 Radixact®系統，這是其 TomoTherapy 技術的先進版本，旨在提高治療速度和臨牀工作流程。</p>
<p>Accuray 的產品系列使臨牀醫生能夠提供高度針對性的放射劑量，同時最大限度地減少對周圍健康組織的暴露。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票比 Accuray 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>麥當勞的秘密</li>
<li>4200 美元的黃金不錯……但這是大多數黃金愛好者所忽視的</li>
<li>特朗普 5000 億美元的計劃正在推動這些每月分紅</li>
<li>100 萬美元在退休後能維持多久？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Accuray 嗎？</h2>
<p>在你考慮 Accuray 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Accuray 並不在名單上。</p>
<p>雖然 Accuray 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

精確射線公司

<p>華爾街禪將 Accuray（NASDAQ:ARAY）的評級從 “持有” 下調至 “賣出”。BTIG 研究也將 Accuray 的目標價格從 5.00 美元下調至 4.00 美元，維持 “買入” 評級。Accuray 的股票開盤價為 0.83 美元，12 個月的價格區間為 0.81 美元至 2.95 美元。該公司報告了季度虧損，未能達到分析師的預期。機構投資者已調整了對該公司的持股。Accuray 專注於癌症治療的放射治療解決方案，產品包括 CyberKnife®和 TomoTherapy®系統</p>

<p>Accuray (NASDAQ:ARAY - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued to clients and investors on Sunday.</p>
<div class="lb-trans"><p>Accuray（納斯達克代碼：ARAY - 獲取免費報告）在週日發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票研究人員將評級從 “持有” 下調至 “賣出”。</p>
</div><p>Other equities research analysts have also issued research reports about the stock. BTIG Research dropped their price objective on shares of Accuray from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Accuray in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $4.00.</p>
<div class="lb-trans"><p>其他股票研究分析師也對該股票發佈了研究報告。BTIG Research 在 11 月 6 日的研究報告中將 Accuray 的目標價格從 5.00 美元下調至 4.00 美元，並對該股票給予了 “買入” 評級。Weiss Ratings 在 12 月 22 日的報告中重申了對 Accuray 的 “賣出（d-）” 評級。一位股票研究分析師給予該股票 “買入” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 4.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on ARAY</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 ARAY 股票分析</strong></p>
</div><h2>Accuray Stock Performance</h2>
<div class="lb-trans"><h2>Accuray 股票表現</h2>
</div><p>ARAY stock opened at $0.83 on Friday. The stock's 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.36. Accuray has a 12-month low of $0.81 and a 12-month high of $2.95. The firm has a market cap of $93.54 million, a P/E ratio of -5.16 and a beta of 1.06. The company has a current ratio of 1.56, a quick ratio of 0.76 and a debt-to-equity ratio of 2.06.</p>
<div class="lb-trans"><p>ARAY 股票在週五開盤價為 0.83 美元。該股票的 50 日簡單移動平均為 1.14 美元，200 日簡單移動平均為 1.36 美元。Accuray 的 12 個月低點為 0.81 美元，12 個月高點為 2.95 美元。該公司的市值為 9354 萬美元，市盈率為-5.16，貝塔值為 1.06。該公司的流動比率為 1.56，速動比率為 0.76，債務與股本比率為 2.06。</p>
</div><p>Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.13). The business had revenue of $93.94 million during the quarter, compared to analyst estimates of $91.34 million. Accuray had a negative return on equity of 34.06% and a negative net margin of 4.28%. As a group, equities research analysts predict that Accuray will post 0.01 EPS for the current year.</p>
<div class="lb-trans"><p>Accuray（納斯達克代碼：ARAY - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。這家醫療設備提供商報告季度每股收益為（0.18 美元），低於分析師共識預期的（0.05 美元）13 美分。該季度的營業收入為 9394 萬美元，而分析師預期為 9134 萬美元。Accuray 的股本回報率為-34.06%，淨利潤率為-4.28%。作為一個整體，股票研究分析師預測 Accuray 在當前年度將發佈 0.01 美元的每股收益。</p>
</div><h2>Institutional Trading of Accuray</h2>
<div class="lb-trans"><h2>Accuray 的機構交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new position in Accuray during the 3rd quarter worth $35,000. Tower Research Capital LLC TRC lifted its holdings in Accuray by 604.2% in the second quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 30,182 shares during the period. BNP Paribas Financial Markets grew its position in Accuray by 32.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,369 shares of the medical equipment provider's stock valued at $66,000 after buying an additional 9,633 shares in the last quarter. Teton Advisors LLC bought a new position in Accuray in the 3rd quarter valued at about $67,000. Finally, R Squared Ltd increased its stake in Accuray by 94.0% during the 3rd quarter. R Squared Ltd now owns 40,550 shares of the medical equipment provider's stock valued at $68,000 after buying an additional 19,648 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了在該公司的持股。俄亥俄州公共僱員退休系統在第三季度新購入了 Accuray 的股份，價值 35,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Accuray 的持股增加了 604.2%。Tower Research Capital LLC TRC 目前擁有 35,177 股該醫療設備提供商的股票，價值 48,000 美元，此前在該期間內又購買了 30,182 股。BNP Paribas Financial Markets 在第三季度將其在 Accuray 的持股增加了 32.4%。BNP Paribas Financial Markets 目前擁有 39,369 股該醫療設備提供商的股票，價值 66,000 美元，此前在上個季度又購買了 9,633 股。Teton Advisors LLC 在第三季度新購入了價值約 67,000 美元的 Accuray 股份。最後，R Squared Ltd 在第三季度將其在 Accuray 的持股增加了 94.0%。R Squared Ltd 目前擁有 40,550 股該醫療設備提供商的股票，價值 68,000 美元，此前在該期間內又購買了 19,648 股。當前 64.08% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Accuray</h2>
<div class="lb-trans"><h2>關於 Accuray</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Accuray Incorporated NASDAQ: ARAY is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company's flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.</p>
<div class="lb-trans"><p>Accuray Incorporated（納斯達克代碼：ARAY）是一家全球醫療設備公司，開發、製造和銷售創新的放射治療解決方案用於癌症治療。該公司的旗艦產品包括 CyberKnife®系統，這是一種提供亞毫米精度的機器人放射外科平台，以及 TomoTherapy®系統，它將螺旋計算機斷層掃描（CT）成像與強度調製放射治療（IMRT）相結合。最近，Accuray 推出了 Radixact®系統，這是其 TomoTherapy 技術的先進版本，旨在提高治療速度和臨牀工作流程。</p>
</div><p>Accuray's suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.</p>
<div class="lb-trans"><p>Accuray 的產品系列使臨牀醫生能夠提供高度針對性的放射劑量，同時最大限度地減少對周圍健康組織的暴露。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Accuray</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>The McDonald's Secret</li>
<li>$4,200 gold is nice ... but here’s what most gold bugs are missing</li>
<li>Trump's $500B plan is fueling these monthly dividends</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Accuray 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>麥當勞的秘密</li>
<li>4200 美元的黃金不錯……但這是大多數黃金愛好者所忽視的</li>
<li>特朗普 5000 億美元的計劃正在推動這些每月分紅</li>
<li>100 萬美元在退休後能維持多久？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Accuray Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Accuray 嗎？</h2>
</div><p>Before you consider Accuray, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Accuray 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Accuray 並不在名單上。</p>
</div><p>While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Accuray 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

精確射線公司（納斯達克代碼：ARAY）的評級在華爾街 Zen 被下調至賣出